Vaxxinity, Inc.

As of December 31, 2023, Vaxxinity, Inc. carries a market capitalization of 107.73M, placing it among publicly traded companies globally. Its enterprise value stands at 92.51M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Vaxxinity, Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of December 31, 2023, Vaxxinity, Inc. has 126.75M shares outstanding.

These figures are as of December 31, 2023.

As of December 31, 2023, Vaxxinity, Inc. maintains a current ratio of 1.89, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 113.12, indicating elevated leverage, while an interest coverage ratio of -80.60 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2023, Vaxxinity, Inc. posted a negative return on equity (ROE) of -150.65, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -75.56, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 81.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Vaxxinity, Inc.'s stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.

Over the twelve months ended December 31, 2023, Vaxxinity, Inc. generated - - in revenue and converted that into -56.93M in net income, yielding earnings per share of -0.45. EBITDA reached -56.10M, while operating income came in at -58.33M.

As of December 31, 2023, Vaxxinity, Inc. holds 30.40M in cash and equivalents against 15.17M in total debt, resulting in a net debt position of 10.24M. Total book value stands at 13.41M, with working capital of 15.63M providing operational flexibility.

Vaxxinity, Inc. produced -57.24M in operating cash flow over the twelve months ended December 31, 2023. After subtracting -803,000.00 in capital expenditures, free cash flow totaled -58.04M - equivalent to -0.46 per share.

These figures cover the twelve months ended December 31, 2023. Free cash flow yield is negative at -53.98: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.06, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Vaxxinity, Inc. shareholders.

As of December 31, 2023, Vaxxinity, Inc. has an Altman Z-Score of -13.25, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.